Form 4: Zenas BioPharma Director Patricia Allen Granted 18,500 Stock Options

Zenas BioPharma, Inc. Director Patricia L. Allen was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Summary

• Patricia L. Allen, a Director of Zenas BioPharma, Inc. (ZBIO), was granted 18,500 stock options.
• The transaction occurred on June 10, 2025, with an exercise price of $11.94 per share.
• The options are scheduled to vest 100% on June 10, 2026, which marks the first anniversary of the vesting commencement date, contingent upon her continued service.
• The expiration date for these stock options is June 10, 2035.
• Following this reported transaction, Patricia L. Allen beneficially owns 18,500 stock options directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed as a positive, routine event that aligns the director's interests with shareholders. It is not indicative of immediate operational or financial performance changes but rather a standard compensation practice.

Positives

• The grant of stock options to a director helps align their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company's success.

Risks

• The ultimate value of the stock options is contingent on Zenas BioPharma's common stock price exceeding the $11.94 exercise price in the future.
• The vesting of the options is subject to Patricia L. Allen's continued service, meaning the options could be forfeited if her service terminates before the vesting date of June 10, 2026.

Future Outlook

This Form 4 filing reports an insider equity transaction and does not contain forward-looking statements regarding the company's operational or financial performance. The future outlook for the granted options depends on the market performance of Zenas BioPharma's common stock relative to the exercise price.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, including for companies like Zenas BioPharma. This type of equity compensation is standard for board members, aiming to align their long-term interests with those of the company's shareholders and to attract and retain qualified talent.

Comparison to Industry Standards

• Equity grants, such as stock options, are a standard component of director compensation packages across publicly traded companies, particularly within the biotechnology sector.
• To assess if this specific grant is in line with industry standards, it would require a comparison of the number of options and their value against compensation practices for directors at companies of similar size, stage of development, and market capitalization within the biotechnology industry. This document alone does not provide sufficient data for such a detailed comparative assessment.

Corporate Governance

Related Party Transactions

• The grant of 18,500 stock options to Patricia L. Allen, a director of Zenas BioPharma, Inc., constitutes a related party transaction as directors are considered related parties to the company.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value, potentially leading to improved performance. It also represents a potential future dilution if options are exercised, which is typical for equity compensation plans.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Patricia L. Allen's continued service to Zenas BioPharma, Inc. is required for the options to vest on June 10, 2026.
• Following vesting, Patricia L. Allen may choose to exercise the options to acquire common stock, depending on the market price of Zenas BioPharma shares.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, SEC filing, insider transaction, stock options, director compensation, equity grant, beneficial ownership, Patricia L. Allen